We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 05, 2022

Serum Neurofilament Light Levels in Natalizumab-Treated Patients With MS Who Switch to Extended-Interval Dosing From Every-4-Week Dosing

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice
Mult. Scler. 2022 Nov 15;[EPub Ahead of Print], J Foley, K Xiong, T Hoyt, CM Singh, E Riddle, C de Moor, T Plavina, N Campbell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading